Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial
在适合移植的新诊断多发性骨髓瘤患者中，使用硼替佐米、沙利度胺和地塞米松联合或不联合达雷妥尤单抗治疗，随后进行达雷妥尤单抗维持治疗或观察：CASSIOPEIA 随机对照 3 期试验的长期随访
期刊:Lancet Oncology
影响因子:35.9
doi:10.1016/S1470-2045(24)00282-1
Moreau, Philippe; Hulin, Cyrille; Perrot, Aurore; Arnulf, Bertrand; Belhadj, Karim; Benboubker, Lotfi; Zweegman, Sonja; Caillon, Hélène; Caillot, Denis; Avet-Loiseau, Hervé; Delforge, Michel; Dejoie, Thomas; Facon, Thierry; Sonntag, Cécile; Fontan, Jean; Mohty, Mohamad; Jie, Kon-Siong; Karlin, Lionel; Kuhnowski, Frédérique; Lambert, Jérôme; Leleu, Xavier; Macro, Margaret; Orsini-Piocelle, Frédérique; Roussel, Murielle; Schiano de Colella, Jean Marc; van de Donk, Niels Wcj; Wuillème, Soraya; Broijl, Annemiek; Touzeau, Cyrille; Tiab, Mourad; Marolleau, Jean-Pierre; Meuleman, Nathalie; Vekemans, Marie-Christiane; Westerman, Matthijs; Klein, Saskia K; Levin, Mark-David; Offner, Fritz; Escoffre-Barbe, Martine; Eveillard, Jean-Richard; Garidi, Réda; Hua, Winnie; Wang, Jianping; Tuozzo, Alba; de Boer, Carla; Rowe, Melissa; Vanquickelberghe, Veronique; Carson, Robin; Vermeulen, Jessica; Corre, Jill; Sonneveld, Pieter
